Pharma Research Library | Pharma Info Index Research | Innovation | Opportunities |
K. Harinadha Baba, Bachalakuri Muni Sai Gagan*, Saritha Chandra
Narayana Pharmacy College, Chinthareddy Palem, Nellore-524003, Andhra Pradesh
A B S T R A C T
Attention-Deficit/Hyperactivity Disorder (ADHD) is a neuro developmental disorder characterized by difficulty paying attention, excessive activity, and impulsivity (acting before you think). ADHD is usually identified when children are in grade school but can be diagnosed at any time from preschool to adulthood. The provision of treatments and interventions for children, young people and their families who have ADHD is varied. Psychological therapies include psychoeducational input, behavioural therapy, cognitive behavioural therapy (CBT) in individual and group formats, interpersonal psychotherapy (IPT), family therapy, school-based interventions, social skills training and parent management training to encourage the development of coping strategies for managing the behavioural disturbance of ADHD. The most commonly used pharmacological drugs atomoxetine, dexamphetamine and methylphenidate are licensed for the management of ADHD in children and young people. Methylphenidate is a central nervous system (CNS) stimulant. Its action has been linked to inhibition of the dopamine transporter, with consequent increases in dopamine available for synaptic.
Keywords: Hyperactivity disorder, ADHD, Children, Psychotherapy, Dopamine
